We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Retreatment after Secondary Resistance or Mixed Response: A Pilot Study.
- Authors
Naing, Aung; Agarwal, Rishi; Falchook, Gerald; Hong, David S.; Janku, Filip; Wheler, Jennifer; Fu, Siqing; Kurzrock, Razelle
- Abstract
Objective: Oncologists usually avoid retreatment with drugs to which patients have shown secondary resistance or a mixed response. Here, we report our findings in a pilot study in patients rechallenged with agents previously producing prolonged stable disease (SD), partial or complete remission (PR/CR) or a mixed response, followed by progression. Results: Eleven individuals with advanced cancers (median number of prior systemic therapies in the metastatic setting = 4, range 2-7) were included (8 men; median age 57 years; median Eastern Cooperative Oncology Group performance status of 1). The median duration between initial treatment and retreatment was 92 weeks. Eight of 11 patients (73%) on a retreatment regimen showed SD ≥24 weeks/PR/CR. Of these 8 individuals, 2 were retreated with the same agent(s), 1 with a different agent possessing the same mechanism of action (e.g., in case of an epidermal growth factor receptor inhibitor, using gefitinib first, then erlotinib), and 5 with the same agent(s) in combination with other agents. Conclusion: Our pilot data suggest that patients who develop acquired resistance after durable SD/CR/PR or who have an initial mixed response may attain SD ≥6 months/PR/CR with a retreatment approach. © 2013 S. Karger AG, Basel
- Subjects
CALIFORNIA; TEXAS; ANTINEOPLASTIC agents; ACADEMIC medical centers; CANCER cells; CELL receptors; EPIDERMAL growth factor; LONGITUDINAL method; CASE studies; TUMORS; PILOT projects; SECONDARY analysis
- Publication
Oncology, 2013, Vol 85, Issue 6, p350
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000355691